# of Displayed Technologies: 10 / 32


Categories

Low-Cost, Multiplexed Microfluidic Force Spectroscopy on-a-Chip
TS-057780 — A novel, low-cost, and massively-parallel force spectroscopy strategy that leverages microfluidic technology to dynamically test strength of molecular binding interactions to enable quick, full characterization of a molecular interaction of interest.
Development of several force spectroscopy strategies have enabled characterization of various types of molecular binding interactions with applications in biophysics, molecular biology and medicine. Despite various efforts to decrease the cost of force spectroscopy, full characterization of a mole…
  • College: College of Engineering (COE)
  • Inventors: Akbari, Ehsan; Castro, Carlos; Shahhosseini, Melika; Song, Jonathan
  • Licensing Officer: He, Panqing

Anti-GARP Monoclonal Antibodies for Cancer Therapy
TS-057778 — A novel monoclonal antibody (PIIO-1) to be used in combination with immune-checkpoint blockers. PIIO-1 augments CD8+ T cells-induced anti-tumor immunity and overcomes ICB resistance by disrupting transforming growth factor-β (TGF-β), the center of a pathway significantly implicated in solid tumors and hematological malignancies. PIIO-1 inhibits TGFβ locally via a docking receptor, avoiding adverse and unforeseen side effects.
Although immune checkpoint blockade (ICB) has emerged as a promising cancer immunotherapy, a majority of tumors fail to respond to ICB. A potential mechanism driving this failed response is the accumulation of TGF-β1 in the tumor microenvironment (TME), which drives immune dysfunction by indu…
  • College: College of Medicine (COM)
  • Inventors: Li, Zihai
  • Licensing Officer: He, Panqing

An Orally Active, Selective Inhibitor of CD4+ T-Cell Activation That Blunts Left-Ventricular Remodeling and Improves Cardiac Function during Chronic Heart Failure
TS-057777 — A novel orally-active drug molecule that can inhibit pathological CD4+ T-cells at clinically translatable doses and, blunts progressive cardiac dysfunction and left-ventricular (LV) remodeling during Heart Failure (HF).
HF afflicts ~6.5 million adults in US with 50% mortality in first 5 years. It has an estimated market size of $4.2B USD in US alone with a forecasted CAGR of 23% from 2018-2028. Current HF treatments are mostly aimed at alleviating symptoms rather than treatment, resulting in progressive cardiac d…
  • College: College of Medicine (COM)
  • Inventors: Bansal, Shyam; Gumina, Richard
  • Licensing Officer: He, Panqing

Albumin-SN-38 Conjugate (AlbuCure) for Cancer Therapy
TS-057776 — A novel protein-drug conjugate of human serum albumin chemically conjugated to SN-38, solubilizing the potent chemotherapeutic. This therapy has the potential to treat many tumors with poor prognosis, including pancreatic, lung, breast, colorectal, ovarian, sarcoma, head and neck cancer, urothelial malignancies, and others.
Many solid tumors have poor prognosis despite recent progress in molecularly targeted therapy and immunotherapy. Irinotecan/CPT-11, a chemotherapy on the WHO Essential Medicines List, is approved for use in colorectal cancer, lung cancer, pancreatic cancer, gastric cancer, malignant glioma, and sa…
  • College: College of Medicine (COM)
  • Inventors: Williams, Terence; Lee, Robert
  • Licensing Officer: He, Panqing

Reduction in Incidence and Severity of Acute Graft-Versus-Host Disease (aGVHD) via CRISPR-Cas9 Deletion of the miR-155 Host Gene (MIR155HG) in Primary Human T Cells
TS-057739 — CRISPR/Cas 9 mediated targeting of MIR155HG in primary human T cells creates genomic deletions that disrupt transcription of mature microRNA-155 (miR-155, a miR associated with inflammation). Applying this treatment to donor T cells prior to allogenic hematopoietic stem cell transplantation (allo-HSCT) when treating hematological malignancies and other primary bone marrow disorders can prevent the development of aGVHD in patients.
The Need More than 8,000 patients receive allo-HSCT annually in the US alone as a cure for hematologic malignancies and other primary bone marrow disorders. However, the major barrier for the success of allo-HSCT is the high incidence of aGVHD and its associated morbidity and mortality. Acute GVHD…
  • College: College of Medicine (COM)
  • Inventors: Ranganathan, Parvathi; Garzon, Ramiro
  • Licensing Officer: He, Panqing

Novel Electrode for Co-factor Regeneration
TS-051995 — Method of regenerating NADPH for the production of biobutanol.
The Need NAD(P)H is used as a reducing co-factor for the synthesis of biochemicals (e.g., conversion of aldehydes to alcohols) using biocatalysts or even microbes. Butanol is an important feedstock used in the chemical industry and shows great potential as a biofuel. Butanol is produced from fossil…
  • College: College of Engineering (COE)
  • Inventors: Kadowaki, Jonathan; Gopalan, Venkat; Jones, Travis; Sengupta, Anindita; Subramaniam, Vishwanath
  • Licensing Officer: He, Panqing

Smart Platform for Engineered Electroceutical Dressings (SPEEDs) Enables Better Wound Care
TS-050245 — An integrated platform with multiple sensing modalities to actively orchestrate antimicrobial activity and wound healing.
Wound healing and disinfection for chronic wounds presents significant hurdles within the medical industry. Current state of art is inadequate and adds a significant cost burden to the healthcare system with many health and life-quality challenges for patients. After the formation of an open wound…
  • College: College of Engineering (COE)
  • Inventors: Prakash, Shaurya; Heald, Rachel; Mohana Sundaram, Prashanth; Narayanan, Kavya; Stoodley, Paul; Subramaniam, Vishwanath; Vilku, Gurleen; Wilgus, Traci; Wozniak, Daniel
  • Licensing Officer: He, Panqing

Novel Natural Product Derivatives Targeting Chronic Diseases
TS-050220 — Novel natural products and derivatives thereof that exhibit potent in vitro and in vivo activity
The Need Metabolic disorders such as type 2 diabetes are a major health concern that have impacted hundreds of millions of adults worldwide. Current pharmaceutical therapies for type 2 diabetes have been associated with adverse reactions including weight gain and increased risk of infection, liver …
  • College: College of Pharmacy
  • Inventors: Carcache de Blanco, Esperanza; Anaya Eugenio, Gerardo David; Eggers, Nicole
  • Licensing Officer: He, Panqing

Targeting circular PCMTD1 in leukemias with p53 mutations
TS-049827 — circPCMTD1 is a novel target in p53 mutated leukemias.
Despite recent progress in understanding acute myeloid leukemia (AML) biology and the use of intensive treatments, the long-term overall survival of non-pediatric AML patients is only 30-40% in young patients (<60 years) and less than 10% in elderly AML patients (>60 years). This highlights &hellip;
  • College: College of Medicine (COM)
  • Inventors: Garzon, Ramiro; Papaioannou, Dimitrios
  • Licensing Officer: He, Panqing

Inhibition of DGAT for the treatment of cancer
TS-049730 — Dysregulated fat metabolism is an established hallmark of cancer cells. However, the disruption of lipid homeostasis in cancer cells remains an elusive target for therapy. Tumor cells acquire abundant fats for rapid cell growth, but how they avoid toxicity from such loading is unknown. An answer t&hellip;
  • College: College of Medicine (COM)
  • Inventors: Guo, Deliang
  • Licensing Officer: He, Panqing

Show More Technologies

Loading icon